Kempf Tibor, Wollert Kai C
Crit Care. 2013 Jul 31;17(4):173. doi: 10.1186/cc12765.
Patients with adult respiratory distress syndrome (ARDS) are highly heterogeneous but current therapies are rather uniform and largely supportive. In the previous issue of Critical Care, Clark and colleagues report that the biomarker GDF-15 provides prognostic information in ARDS that is additive to that provided by the APACHE III score. Patients with high levels of growth-differentiation factor 15 (GDF-15) had a higher mortality and more complicated hospital course. Biomarkers such as GDF-15 may help us to identify patients at higher risk who may eventually benefit from more personalized and targeted therapies.
患有成人呼吸窘迫综合征（ARDS）的患者具有高度异质性，但目前的治疗方法较为统一且主要是支持性的。在上一期《重症监护》杂志中，克拉克及其同事报告称，生物标志物生长分化因子15（GDF-15）在ARDS中提供的预后信息是对急性生理与慢性健康状况评分系统Ⅲ（APACHE III）评分所提供信息的补充。生长分化因子15（GDF-15）水平较高的患者死亡率更高，住院过程也更复杂。诸如GDF-15这样的生物标志物可能有助于我们识别出风险较高的患者，这些患者最终可能会从更个性化、更具针对性的治疗中获益。
